A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Not Recruiting

Trial ID: NCT01876251

Purpose

This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.

Official Title

Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer

Stanford Investigator(s)

Mark Pegram

Susy Yuan-Huey Hung Professor

Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.

Professor of Medicine (Oncology) and of Epidemiology and Population Health

Eligibility


Inclusion Criteria:

   - Diagnosis of breast cancer with evidence of a) metastatic or b) locally
   recurrent/advanced disease.

Exclusion Criteria:

   - Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.

Intervention(s):

drug: PF-03084014

drug: PF-03084014

drug: PF-03084014

drug: Docetaxel

drug: Docetaxel

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.